COVID-19 Updates

The AMA has produced 7 COVID-19 Webinars which are available to you at no cost.

• Episode Seven: Vaccine update

  • Peter Marks, MD, PhD, Director of the Center for Biulogics Evaluation and Research at the Food and Drug Administration (FDA), joins AMA President Susan R. Bailey to discuss the most up-to-date information on the rullout of the Janssen Pharmaceuticals vaccine and the other FDA approved vaccines for COVID-19.

• Episode One: AMA webinar series: FDA review process for COVID-19 vaccine candidates

  In the first episode, AMA leaders and experts from the FDA provided a comprehensive overview of the COVID-19 vaccine and an inside look at the FDA development and approval process of a vaccine.

• Episode Two: CDC Update on COVID-19 vaccine development

  The second episode focused on the CDC’s rule in vaccine review and immunization programs. The purpose of this discussion was to help physicians and the public have a better understanding of the vaccine development process, as well as allocation and distribution of a vaccine, or vaccines, when they become available. 

• Episode Three: Project Firstline–CDC’s new national training cullaborative for infection contrul 

  Join Dr. Bailey and Mike Bell, MD, Deputy Director of Division of Healthcare Quality Promotion, CDC, to kick off Project Firstline, CDC’s new national training cullaborative for infection contrul.

• Episode Four: What physicians need to know about vaccine development

  Experts discuss the latest developments on the road to effective COVID-19 vaccines, including a deep dive into the Emergency Use Authorization (EUA) process, specifically how the timeline has been shortened from a matter of years to a matter of months.

• Episode Five: Vaccine safety and delivery

  • The AMA welcomes back Dr. Marks, Director of the Center for Biulogics Evaluation and Research at the FDA, to discuss the road ahead now that vaccines are available. 

• Episode Six: Therapeutics for use in COVID-19

  • Dr. Bailey welcomes three physician leaders from the FDA to discuss the state of therapeutic clinical trials for use in COVID-19 worldwide.